Sacubitril + Valsartan

  • Medicine name- Cidmus
  • API– Sacubitril Valsartan
  • Packaging-Tablets
  • Strength– 24/26 mg; 49/51 mg; 97/103 mg
  • Manufactured byDr Reddy’s Laboratories Ltd
Get an Enquiry

Description

In adult patients with chronic heart failure, Cidmus (Sacubitril + Valsartan) tablet is recommended to lower the risk of cardiovascular death and hospitalization due to heart failure. 

  • Patients having a left ventricular ejection fraction (LVEF) below normal definitely show the greatest benefits. 
  • For the management of pediatric patients one year of age and older who have symptomatic heart failure associated with systemic left ventricular systolic dysfunction.
  • It is anticipated that Sacubitril Valsartan will enhance cardiovascular outcomes by lowering NT-proBNP.

Dosage and Side Effects

  • The recommended initial dosage of sacubitril valsartan is 49/51 mg taken orally twice daily. After 2 to 4 weeks, increase the dosage to the desired maintenance level of 97/103 mg twice daily, as long as it’s well tolerated by the patient.

  • For patients not currently using an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB), or those who previously took a low dose of these medications, individuals with severe kidney impairment, and patients with moderate liver impairment, start with a lower dose of sacubitril/valsartan at 24/26 mg twice a day. Then, gradually double the dose every two to four weeks until reaching the maintenance dose of 97/103 mg twice a day, provided it’s well tolerated.

  • The most frequently observed side effects associated with Sacubitril Valsartan include hyperkalemia, kidney problems, low blood pressure, cough, and dizziness.

Warning and Precautions

  • Sacubitril/valsartan use can pose risks of fetal harm if administered during pregnancy. Medications affecting the renin-angiotensin system in the 2nd and 3rd trimesters can reduce fetal renal function and increase fetal and neonatal mortality.

  • Concomitant use of Sacubitril/Valsartan with an angiotensin-converting enzyme (ACE) inhibitor is not recommended. Switching from an ACE inhibitor to Sacubitril/Valsartan requires a 36-hour washout period between the two medications.

  • Sacubitril/valsartan generics may trigger angioedema. If angioedema occurs, promptly discontinue the medication, provide appropriate treatment, and assess for airway complications.

  • Patients with a history of angioedema may face an increased risk when using sacubitril/valsartan. It is contraindicated in patients with a history of angioedema related to previous ACE inhibitors or ARB therapy and in those with hereditary angioedema.

  • Sacubitril/valsartan tablets can lower blood pressure, potentially causing symptomatic hypotension. Patients with an activated renin-angiotensin system or those who are volume- or salt-depleted (such as those on high diuretic doses) are at greater risk.

  • Regularly monitor serum creatinine levels and consider reducing or discontinuing sacubitril/valsartan therapy in patients experiencing a significant decline in renal function.

  • Like other medications affecting the RAAS, sacubitril and valsartan tablets may elevate blood urea and serum creatinine levels in individuals with unilateral or bilateral renal artery stenosis. Assess renal function in such cases.

  • Hyperkalemia may result from the drug’s action on the RAAS. Monitor serum potassium periodically, especially in patients with risk factors such as diabetes, severe renal impairment, hypoaldosteronism, or a high potassium diet. Adjustment or interruption of sacubitril/valsartan dosage may be necessary.

FAQ's

What exactly is Sacubitril Valsartan used for?

Sacubitril Valsartan tablet is a medication approved to manage chronic heart failure in adults, aiming to reduce the risk of both hospitalization and mortality. It is particularly effective when the heart struggles to pump blood adequately throughout the body.

What are the available dosage strengths of Sacubitril Valsartan?

Sacubitril/Valsartan comes in three strengths:

  • Sacubitril/Valsartan 24/26 mg
  • Sacubitril/Valsartan 49/51 mg
  • Sacubitril/Valsartan 97/103 mg

How is Sacubitril Valsartan administered?

Sacubitril Valsartan is a film-coated tablet designed for oral administration.

What class of medication does Sacubitril Valsartan belong to?

Sacubitril and valsartan together form an FDC and belong to a class of medications known as angiotensin receptor neprilysin inhibitors (ARNI).

Where can I obtain Sacubitril Valsartan Tablets?

You can purchase Sacubitril Valsartan tablet from authorized wholesalers upon presenting a prescription from a qualified doctor. It’s recommended to verify the credentials of the wholesaler, supplier, or exporter before making the purchase, and to ensure compliance with the laws and regulations of your home country regarding the importation of this product.